Phase 1 Study of an Inactivated Vaccine against American Tegumentary Leishmaniasis in Normal Volunteers in Brazil

Memorias do Instituto Oswaldo Cruz

Volumn 93, Issue 2, 1998, Pages 205-212

  Marzochi, Keyla B F ^c   Marzochi, Mauro C A ^a   Silva, Aline F ^a   Grativol, Neiva ^c   Duarte, Rosemere ^a   Confort, Eliame Mouta ^a   Modabber, Farrokh ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Leishmania; Montenegro skin test; Phase 1 study; Side effects; Vaccine

Indexed keywords

LEISHMANIA AMAZONENSIS;

INACTIVATED VACCINE; PROTOZOAL VACCINE;

ADULT; ANIMAL; ARTICLE; BRAZIL; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNOLOGY; LEISHMANIA MEXICANA; MALE; PHASE 1 CLINICAL TRIAL; SKIN LEISHMANIASIS; SKIN TEST;

ADULT; ANIMALS; BRAZIL; CLINICAL TRIALS, PHASE I; DOUBLE-BLIND METHOD; HUMANS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MALE; PROTOZOAN VACCINES; SKIN TESTS; VACCINES, INACTIVATED;

EID: 0032018002     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02761998000200014     Document Type: Article

References (38)

1. Alimohammadian MH, Kivanjah M, Pak F, Gaznavia A, Kharazmi A 1993. Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins from Wellcome (UK) and Roma (Italy) in cured cutaneous leishmaniasis patients. Trans R Soc Trop Med Hyg 87: 550-551.
2. Antunes CMF, Mayrink W. Magalhães PM, Costa CA, Melo MN, Dias M, Michalick M, Willians P, Oliveira Lima A, Vieira JBF, Schettini APM 1986. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Inst J Epidemiol 15: 572-579.
3. Badarȯ R, Johnson Jr WD 1993. The role of Interferongamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 167 (Suppl. 1): 513.
4. Bryceson A 1987. Therapy in man, p. 847-907. In W Peters, R Killick-Kendrick (eds). The Leishmaniasis in Biology and Medicine. Clinical aspects and Control, vol 2: Academic Press, London & New York.
5. Castés M, Blackwell J, Trujillo D, Formica S, Cabrera M. Zorrilla G, Rodas A, Castellanos PL, Convit J 1994. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: skin-test reactivity, T-ceil proliferation and interferon-gamma production. Vaccine 12: 1041-1051.
6. Convit J, Ulrich M, Fernandez CT, Tapia FJ, CáceresDittmar G, Castés M, Rondón AJ 1993. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 87: 444-448.
7. Cordova-Uscanga CMC, Alpuche NEA, Narváez FJA 1993. Leishmaniasis: estudio epidemiológico en una localidad de la zona endémica del Estado de Tabasco. Salud Publ de Mexico 35: 345-350.
8. De La Quadra J 1993. Cutaneous sensitivity to mercury and its compounds. Ann Dermatol Venereol 120: 37-42.
9. Desjeux P 1992. Human leishmaniasís: epidemiology and public health aspects World Health. Statistical Quarterly 45: 1-6.
10. Furtado T 1980. Critérios para o diagnóstico da leishmaniose tegumentar americana. An Bras Dermatol 55: 81-86.
11. Guerra MOP, Furrtado T, Barros GC, Sessa PA, Daher VR 1985. Infecção subclinica na leishmaniose tegumentar americana. An Bras Dermatol 60: 365-369.
12. Handley J, Todd D, Burrows D 1993. Mercury allergy in a contact dermatitis clinic in Northern Ireland. Contact dermatitis 29: 258-261.
13. Isaza MR 1980. La reacion de Montenegro en la epidemiologia de la leishmaniasis sudamericana. Boletin Oficina Sanitaria Panamericana 89: 130-136.
14. Kadaro AY, Ghalib HW, Ali MS, Eltoun I, Ismail A, Gaafar A, Kemp M, Kordofani AAY, Reed SG, El-Hassan AM, Kharazmi A, Hag-Ali M, Mustafa MD 1993. Prevalence of cutaneous leishmaniasis along the Nile river North of Khartoum (Sudan) in the aftermath of an epidemic in 1985. Am J Trop Med Hyg 48: 44-49.
15. Lainson R, Shaw JJ, Silveira FT, de Souza AAA, Braga RR, Ishikawa EAY 1994. The dermal leishmaniases of Brazil with special reference to the eco-epidemiology of the disease in Amazônia. Mem Inst Oswaldo Cruz 89: 435-443.
16. Mallory SD 1987. Allergic contact dermatitis. Immunol Allergy Clin North Amer 7: 407-421.
17. Manson-Bahr PEC 1987. Diagnosis, p. 703-729. In W Peters, R Killick-Kendrick (eds). The Leishmaniases in Biology and Medicine. Clinical aspects and Control, vol 2, Academic Press, London & New York.
18. Marzochi MCA 1992. Leishmanioses no Brasil: as leishmanioses tegumentares. J Bras Med 63: 82-104.
19. Marzochi MCA, Marzochi KBF 1994. Tegumentary and visceral leishmaniases in Brazil - Emerging anthropozoonosis and possibilities for their control. Cad Saú Púb 10 (Supl. 2): 359-375.
20. Marzochi MCA, Coutinho SG, Sabroza PC, Souza WJ 1980. Reação de imunofluorescência indireta e intradermorreação para leishmaniose tegumentar americana em moradores na area de Jacarepaguá (Rio de Janeiro): Estudo comparativo dos resultados observados em 1974 e 1978. Rev Inst Med Trop São Paulo 22: 149-155.
21. Mayrink W, Costa CA, Magalhães PA, Melo MN, Dias M, Oliveira Lima A, Michalick MS, Willians P 1979. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg 73: 385-387.
22. Mayrink W, Willians P, Costa CA, Magalhães A, Melo MN, Dias M, Oliveira Lima A, Michalick MS, Ferreira Carvalho E, Barros GC, Sessa PA, Alencar JTA 1985. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espírito Santo Brazil. Ann Trop Med Parasitol 79: 259-269.
23. Melo MN, Mayrink W, Costa CA, Magalhães PA, Dias M, Willians P, Araújo FG, Coelho MV, Batista SM 1977. Padronização do antígeno de Montenegro. Rev Inst Med Trop São Paulo 19: 161-164.
24. Monjour L, Neogy AB, Vouldoukis I, Silva OA, Boisnic S, Brito MEF, Lesot A, Vignot N, Martins JS, Jarsin ML 1994. Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in Brasil. Mem Inst Oswaldo Cruz 89: 435-443.
25. Montenegro J 1926. Cutaneous reaction in leishmaniasis. Archives Dermatol Syphilis 13: 187-194.
26. Moriearty PL, Pereira C, Guimarães NA 1978. Contact dermatitis in Salvador, Brazil. Contact dermatitis 4: 185-189.
27. Nadim A 1990. Leishmanization as a control measure in Iran. In UNDP/WORLD BANK/WHO/TDR Meeting on vaccines against Leishmaniasis, Belo Horizonte.
28. Nascimento MDSB, Alcãntara-Neves NM, Muniz MEB, Nunes SF, Paranhos M, Pontes de Carvalho LC 1993. Induction and modulation of the immune response to Leishmania by Montenegro skin test. Trans R Soc Trop Med Hyg 87: 91-93
29. Oliveira-Filho AM, Melo MTV 1994. Vectors control importance on leishmaniasis transmission. Mem Inst Oswaldo Cruz: 89: 4451-456.
30. Olliaro PL, Bryceson ADM 1993. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 9: 323-328.
31. Pessoa SB 1941. Segunda nota sobre a vacinação preventiva na Leishmaniose Tegumentar Americana com leptomonas mortas. Rev Paulisia Med 19: 1-9.
32. Pessoa SB, Pestana BR 1940. Ensaio sobre a vacinação preventiva na Leishmaniose Tegumentar Americana com germes mortos. Rev Biol Higiene 10 : 112-118
33. Salles Gomes L 1939. A intradermorreação de Montenegro na leishmaniose e outras pesquisas afins. Brasil Méd 49: 5-15.
34. Scarpa C, Kokelj F, Stinco G, Lavaroni G 1992. Allergic contact dermatitis in Trieste from 1987-1991. Aller Immunol Paris 24: 390-392.
35. Sokal JE 1975. Measurement of delayed skin-test responses. N Engl J Med 293: 501-502.
36. Stolf HO, Alencar Marques S, Marques EA, Yoshida ELA, Dillon NL 1993. Surto de leishmaniose tegumentar em Itaporanga São Paulo (Brasil). Rev Inst Med Trop São Paulo 35: 437-442.
37. Voller A, Bartlett A, Bidwell DE 1976. Enzyme immunoassays with special reference to ELISA thecniques. J Clin Pathol 31: 507-520.
38. Zijlstra EE, El-Hassan AM 1993. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan with special reference to kala-azar. Trans R Soc Trop Med Hyg 87: 425-427.